Inactive Instrument

Echo Therapeutics, Inc.

Equities

ECTE

US27876L2060

Advanced Medical Equipment & Technology

Echo Therapeutics, Inc. Announces Institutional Review Board Approval for its Clinical Trial of the Symphony(R) CGM System

May 21, 2013 at 07:50 am EDT

Echo Therapeutics, Inc. announced that the company's clinical trial of its Symphony CGM System has received Institutional Review Board (IRB) approval. The IRB approval enables the commencement of a clinical evaluation of Symphony that will support the Company's CE Mark Technical File.

Latest news about Echo Therapeutics, Inc.

Echo Therapeutics, Inc. Appoints Alan W. Schoenbart as Chief Executive Officer	17-03-22	CI
Echo Therapeutics, Inc. Appoints Alan W. Schoenbart as Interim Chief Executive Officer	16-11-23	CI
Echo Therapeutics, Inc. Announces Resignation of Dr. Elazer Edelman as Member of the Board of Directors and Audit Committee	16-09-27	CI
Echo Therapeutics, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2016	16-08-12	CI
Echo Therapeutics, Inc.(OTCPK:ECTE) dropped from S&P TMI Index	16-07-13	CI
Echo Therapeutics, Inc. Primary Exchange Listing will Change to OTCQB Marketplace from Nasdaq Capital Market	16-07-12	CI
Echo Therapeutics, Inc.(NasdaqCM:ECTE) dropped from NASDAQ Composite Index	16-07-11	CI
Echo Therapeutics, Inc. Announces Institutional Review Board Approval of New Protocol	16-06-13	CI
Echo Therapeutics Seeks Acquisitions	16-06-10	CI
Echo Therapeutics, Inc. Announces New Appointments	16-05-26	CI
Echo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2016	16-05-20	CI
Echo Therapeutics, Inc. announced that it has received $4.47 million in funding.	16-05-02	CI
Echo Therapeutics, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2015	16-03-30	CI
Echo Therapeutics Issues Promissory Note to Platinum Partners Value Arbitrage Fund	16-03-22	CI
Echo Therapeutics, Inc. announced that it expects to receive $4.47 million in funding.	16-01-28	CI
Echo Therapeutics, Inc. Appoints Elazer Edelman to its Board of Directors	15-12-28	CI
Echo Therapeutics, Inc. Announces Earnings Results for the Third Quarter Ended September 30, 2015	15-11-16	CI
Echo Therapeutics, Inc. announced that it expects to receive $0.32 million in funding from Beijing Yi Tang Bio Science & Technology, Ltd., Platinum Management (NY) LLC, and another investor.	15-09-23	CI
Echo Therapeutics, Inc. announced that it expects to receive $0.15 million in funding from Platinum Management (NY) LLC and Beijing Yi Tang Bio Science & Technology, Ltd.	15-08-26	CI
Echo Therapeutics, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2015	15-08-14	CI
Worldwide Business with kathy ireland® Selects Echo Therapeutics, Inc. for Wearable Technology Feature	15-05-26	CI
Echo Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015	15-05-15	CI
Echo Therapeutics, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2014	15-04-15	CI
Echo Therapeutics, Inc. Reports Revised Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014	15-04-15	CI
Echo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	15-04-14	CI

Chart Echo Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Echo Therapeutics, Inc. is a medical device company. The Company is engaged in developing a non-invasive, wireless continuous glucose monitoring (CGM) system with use in the wearable-health consumer market, diabetes outpatient market and in the hospital setting. The Company operates through the development of transdermal skin permeation and diagnostic medical devices segment. The Company has also developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, enhanced delivery of topical pharmaceuticals and other applications. The CGM System includes a skin preparation device, transdermal glucose sensor, battery and wireless transmitter. The Company has conducted several human feasibility clinical studies with its CGM System in healthy subjects, diabetics and critically ill patients, as well as a clinical study at several hospitals in the United States.

Sector

Advanced Medical Equipment & Technology

More about the company

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
THERMO FISHER SCIENTIFIC	+7.01%	217B
DANAHER CORPORATION	+11.01%	190B
INTUITIVE SURGICAL, INC.	+19.20%	143B
BOSTON SCIENTIFIC CORPORATION	+30.79%	111B
SIEMENS HEALTHINEERS AG	+1.48%	64.59B
EDWARDS LIFESCIENCES CORPORATION	+13.95%	52.36B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.16%	48.45B
AGILENT TECHNOLOGIES, INC.	-6.20%	38.03B
GE HEALTHCARE TECHNOLOGIES INC.	+0.91%	35.61B

Other Advanced Medical Equipment & Technology